Optimization of a rat lumbar IVD degeneration mannequin for low again ache
Introduction: Intervertebral disc (IVD) degeneration is commonly related to low again ache and radiating leg ache. The aim of this examine is to develop a reproducible and standardized preclinical mannequin of painful lumbar IVD degeneration by analysis of structural and behavioral modifications in response to IVD damage with growing needle sizes. This mannequin can be utilized to develop new therapies for IVD degeneration.
Strategies: Forty-five feminine Sprague Dawley rats underwent anterior lumbar disc needle puncture at ranges L4-5 and L5-6 underneath fluoroscopic steerage. Animals have been randomly assigned to 4 completely different experimental teams: needle sizes of 18 Gauge (G), 21G, 23G, and sham management. To watch the development of IVD degeneration and ache, the next strategies have been employed: μMRI, qRT-PCR, histology, and biobehavioral evaluation.
Outcomes: T1- and T2-weighted μMRI evaluation confirmed a correlation between the diploma of IVD degeneration and needle diameter, with probably the most extreme degeneration within the 18G group. mRNA expression of markers for IVD degeneration markers have been dysregulated within the 18G and 21G teams, whereas pro-nociceptive markers have been elevated within the 18G group solely. Hematoxylin and Eosin (H&E) and Alcian Blue/Picrosirius Purple staining confirmed probably the most pronounced IVD degeneration within the 18G group. Randall-Selitto and von Frey checks confirmed elevated hindpaw sensitivity within the 18G group.
Conclusion: Our findings show that anterior disc damage with an 18G needle creates extreme IVD degeneration and mechanical hypersensitivity, whereas the 21G needle ends in average degeneration with no elevated ache sensitivity. Subsequently, needle sizes ought to be chosen relying on the specified phenotype for the pre-clinical mannequin.

itlhealthcare
Gentamicin-BSA |
80-IG10 |
Fitzgerald |
25 mg |
EUR 457.2 |
Description: Conjugated Gentamicin-BSA hapten |
BSA Control for Age-BSA |
2221-BSA |
Biovision |
each |
EUR 210 |
Bovine Serum Albumin Biotinylated (Biotin-BSA) |
BTN-BSA |
Alpha Diagnostics |
5 mg |
EUR 343.2 |
Ibrutinib drug-Bovine Serum Albumin (BSA) Conjugate |
IBT15-BSA |
Alpha Diagnostics |
100 ug |
EUR 634.8 |
Dinitrophenyl (DNP)-BSA protein Conjugate |
AV-9330-BSA |
Alpha Diagnostics |
10 mg |
EUR 343.2 |
mPEG-BSA (Molecular Weight: 5,000-linear) |
PEG-BSA-05K |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
mPEG-BSA (Molecular Weight: 10,000-linear) |
PEG-BSA-10K |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
mPEG-BSA (Molecular Weight: 20,000-linear) |
PEG-BSA-20K |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
mPEG-BSA (Molecular Weight: 40,000-linear) |
PEG-BSA-40K |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
Gentamicin-HRP |
65-IG10 |
Fitzgerald |
1 mg |
EUR 716.4 |
Description: Conjugated Gentamicin-HRP hapten |
Gentamicin antibody |
10-1541 |
Fitzgerald |
100 ug |
EUR 470.4 |
Description: Mouse monoclonal Gentamicin antibody |
Gentamicin antibody |
10-G02A |
Fitzgerald |
500 ug |
EUR 591.6 |
Description: Mouse monoclonal Gentamicin antibody |
Gentamicin antibody |
20C-CR1031S |
Fitzgerald |
1 ml |
EUR 262.8 |
Description: Sheep polyclonal Gentamicin antiserum |
Gentamicin antibody |
20-GG15 |
Fitzgerald |
250 ul |
EUR 220.8 |
Description: Goat polyclonal Gentamicin antibody |
Gentamicin antibody |
20-GR15 |
Fitzgerald |
250 ul |
EUR 249.6 |
Description: Rabbit polyclonal Gentamicin antibody |
Gentamicin Antibody |
abx021011-200ug |
Abbexa |
200 ug |
EUR 393.6 |
|
Gentamicin Antibody |
abx021012-1mg |
Abbexa |
1 mg |
EUR 1144.8 |
|
Gentamicin Antibody |
abx021013-1mg |
Abbexa |
1 mg |
EUR 577.2 |
|
Gentamicin Antibody |
20-abx210193 |
Abbexa |
|
|
|
Gentamicin-OVA |
80-1455 |
Fitzgerald |
1 mg |
EUR 781.2 |
Description: OVA conjugated Gentamicin Hapten |
Gentamicin-OVA |
80-1456 |
Fitzgerald |
1 mg |
EUR 781.2 |
Description: OVA conjugated Gentamicin Hapten |
Gentamicin sulfate |
B1270-1G |
Biovision |
each |
EUR 170.4 |
Gentamicin sulfate |
B1270-25G |
Biovision |
each |
EUR 1136.4 |
Gentamicin sulfate |
B1270-5G |
Biovision |
each |
EUR 405.6 |
(DRAAGQPAG)3 peptide (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP) conjugated with BSA |
DRAA31-BSA |
Alpha Diagnostics |
0.5 mg |
EUR 634.8 |
(PPPPNAND)3 peptide (repeat-sequence peptide of the P. berghei circumsporozoite protein, CSP) conjugated with BSA |
PPPP321-BSA |
Alpha Diagnostics |
0.5 mg |
EUR 634.8 |
(NVDP)4 peptide (minor repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) conjugated with BSA |
NVDP41-BSA |
Alpha Diagnostics |
0.5 mg |
EUR 634.8 |
Gentamicin Solution, Gentamicin Solution, 50 mg/mL |
CCM1123-010 |
Bio Basic |
10 mL |
EUR 76.86 |
|
(NANP)5 peptide (25-aa, repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) conjugated with BSA |
NANP51-BSA |
Alpha Diagnostics |
0.5 mg |
EUR 634.8 |
Bovine Serum Albumin (BSA) ELISA Kit |
DLR-BSA-Ge-48T |
DL Develop |
48T |
EUR 464.4 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Bovine Serum Albumin (BSA) ELISA Kit |
DLR-BSA-Ge-96T |
DL Develop |
96T |
EUR 592.8 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Bovine serum albumin (BSA) removal kit (Antibody based aff matrix; sufficient to remove 1-2 mg BSA from Bioprocessed material), 2 ml aff column |
800-302-BSA |
Alpha Diagnostics |
1 Kit |
EUR 416.4 |
Bovine serum albumin (BSA) removal kit (Antibody based aff matrix; sufficient to remove 10-20 mg BSA from Bioprocessed material), 10 ml aff column |
800-310-BSA |
Alpha Diagnostics |
1 Kit |
EUR 1074 |
Bovine serum albumin (BSA) removal kit (Antibody based aff matrix; sufficient to remove 25-50 mg BSA from Bioprocessed material), 25 ml aff column |
800-325-BSA |
Alpha Diagnostics |
1 Kit |
EUR 1740 |
General Bovine Serum Albumin (BSA) ELISA Kit |
RD-BSA-Ge-48Tests |
Reddot Biotech |
48 Tests |
EUR 632.4 |
General Bovine Serum Albumin (BSA) ELISA Kit |
RD-BSA-Ge-96Tests |
Reddot Biotech |
96 Tests |
EUR 878.4 |
General Bovine Serum Albumin (BSA) ELISA Kit |
RDR-BSA-Ge-48Tests |
Reddot Biotech |
48 Tests |
EUR 661.2 |
General Bovine Serum Albumin (BSA) ELISA Kit |
RDR-BSA-Ge-96Tests |
Reddot Biotech |
96 Tests |
EUR 919.2 |
Gentamicin ELISA kit |
55R-2233 |
Fitzgerald |
1 kit |
EUR 837.6 |
Description: Gentamicin ELISA kit for use in research laboratory |
Gentamicin monoclonal antibody |
10R-11497 |
Fitzgerald |
1 mg |
EUR 1332 |
Description: Mouse anti- Gentamicin monoclonal antibody |
Gentamicin sulfate salt |
20-abx082235 |
Abbexa |
|
|
|
Gentamicin (GTM) Antibody |
20-abx175177 |
Abbexa |
-
EUR 393.60
-
EUR 994.80
-
EUR 526.80
-
EUR 184.80
-
EUR 309.60
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Gentamicin ELISA Kit |
DEIA047 |
Creative Diagnostics |
96T |
EUR 1238.4 |
Description: This kit can be used in quantitative and qualitative analysis of gentamicin residue in vaccine and cell culture. |
Gentamicin, 50mg/ml |
CA003-001 |
GenDepot |
10ml |
EUR 109.2 |
Gentamicin Sulfate USP |
G006-25G |
TOKU-E |
25 g |
EUR 470.4 |
Gentamicin Sulfate USP |
G006-5G |
TOKU-E |
5 g |
EUR 199.2 |
Gentamicin Sulfate EP |
G007-25G |
TOKU-E |
25 g |
EUR 478.8 |
Gentamicin Sulfate EP |
G007-5G |
TOKU-E |
5 g |
EUR 219.6 |
Gentamicin ELISA Kit |
K4206-100 |
Biovision |
each |
EUR 1188 |
Vaccigel Alum adjuvant adsorbed with Bovine Serum Albumin (BSA @1 mg/ml), Vaccine adjuvant |
AV-1010-BSA |
Alpha Diagnostics |
1 ml |
EUR 343.2 |
Pre-diluted BSA (bovine serum albumin) standards (1 set) for BCA Optima Protein Assay kit |
BCA-BSA-1 |
Alpha Diagnostics |
1 pk |
EUR 196.8 |
Pre-diluted BSA (bovine serum albumin) standards (750 ug/ml) for BCA Optima Protein Assay kit |
BCA-BSA-750 |
Alpha Diagnostics |
1 ml |
EUR 270 |
Gentamicin ELISA Kit (OKAO00127) |
OKAO00127 |
Aviva Systems Biology |
96 Wells |
EUR 638.4 |
Description: Description of target: Gentamicin is a complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.;Species reactivity: General;Application: ;Assay info: Assay Methodology: Competitive Inhibition ELISA;Sensitivity: Component | Amount | _x000D_Tissue | 6 ppb | _x000D_Liver | 10 ppb | Milk | 15 ppb | _x000D_Serum | 6 ppb | _x000D_
|
BSA and BGG Stock standards (1 vial each @ 2 mg/ml) for BCA Optima Protein Assay kit |
BSA-BGG-1 |
Alpha Diagnostics |
1 pk |
EUR 343.2 |
Pre-diluted BSA (bovine serum albumin) standards (250, 125, 62.5, 31.25, and 0.0 ug/ml) for BCA Optima Protein Assay kit |
BCA-BSA-2 |
Alpha Diagnostics |
1 pk |
EUR 196.8 |
Gentamicin C1 Sulfate EvoPure® |
G031-10MG |
TOKU-E |
10 mg |
EUR 804 |
Gentamicin C1a sulfate EvoPure® |
G032-10MG |
TOKU-E |
10 mg |
EUR 804 |
Gentamicin C2 sulfate EvoPure® |
G033-10MG |
TOKU-E |
10 mg |
EUR 804 |
Gentamicin C2a sulfate EvoPure® |
G034-10MG |
TOKU-E |
10 mg |
EUR 804 |
Gentamicin A sulfate EvoPure® |
G035-10MG |
TOKU-E |
10 mg |
EUR 456 |
Gentamicin X2 sulfate EvoPure® |
G036-2.5MG |
TOKU-E |
2.5 mg |
EUR 36 |
Gentamicin X2 sulfate EvoPure® |
G036-PleaseContactusforPricing |
TOKU-E |
Please Contact us for Pricing |
EUR 36 |
Gentamicin C2b sulfate EvoPure® |
G062-10MG |
TOKU-E |
10 mg |
EUR 615.6 |
Gentamicin (serum/urine) ELISA Kit |
K4315-100 |
Biovision |
each |
EUR 907.2 |
GTTR [Texas Red gentamicin conjugate] |
24300 |
AAT Bioquest |
100 ug |
EUR 203 |
GTTR [Texas Red gentamicin conjugate] |
24301 |
AAT Bioquest |
1 mg |
EUR 989 |
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 20-40 mg BSA from Bioprocessed material), 2 ml aff column |
800-200-BSA |
Alpha Diagnostics |
1 kit |
EUR 343.2 |
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 50-100 mg BSA from Bioprocessed material), 5 ml aff column |
800-205-BSA |
Alpha Diagnostics |
1 kit |
EUR 927.6 |
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 250-500 mg BSA from Bioprocessed material), 25 ml aff column |
800-225-BSA |
Alpha Diagnostics |
1 kit |
EUR 2910 |
BSA |
31C-CH0114 |
Fitzgerald |
50 mg |
EUR 159.6 |
Description: Bovine Serum Albumin for use in the research laboratory |
BSA Control for AGE-BSA |
35R-AA007 |
Fitzgerald |
10 mg |
EUR 268.8 |
Description: BSA Control for AGE protein (BSA modified), Cat No. 30R-AA007 |
Testosterone 3 BSA Protein (BSA) |
abx060856-1mg |
Abbexa |
1 mg |
EUR 693.6 |
|
Ibrutinib drug-Human Serum Albumin Conjugate |
IBT16-BSA |
Alpha Diagnostics |
100 ug |
EUR 634.8 |
HEPES-TL Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make HEPES-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVL01-500ML |
Caisson Labs |
500 ml |
EUR 104.4 |
|
Description: Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make HEPES-TALP (Tyrode's Albumin Lactate Pyruvate). |
HEPES-TL Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make HEPES-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVL01-6X500ML |
Caisson Labs |
6 x 500 ml |
EUR 226.8 |
|
Description: Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make HEPES-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVF-TL Supplement with BSA (EFAF), sodium pyruvate, gentamicin, and heparin to make IVF-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVL02-100ML |
Caisson Labs |
100 ml |
EUR 90 |
|
Description: Supplement with BSA (EFAF), sodium pyruvate, gentamicin, and heparin to make IVF-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVF-TL Supplement with BSA (EFAF), sodium pyruvate, gentamicin, and heparin to make IVF-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVL02-6X100ML |
Caisson Labs |
6 x 100 ml |
EUR 154.8 |
|
Description: Supplement with BSA (EFAF), sodium pyruvate, gentamicin, and heparin to make IVF-TALP (Tyrode's Albumin Lactate Pyruvate). |
SP-TL Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make SP-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVL03-100ML |
Caisson Labs |
100 ml |
EUR 86.4 |
|
Description: Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make SP-TALP (Tyrode's Albumin Lactate Pyruvate). |
SP-TL Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make SP-TALP (Tyrode's Albumin Lactate Pyruvate). |
IVL03-6X100ML |
Caisson Labs |
6 x 100 ml |
EUR 126 |
|
Description: Supplement with BSA (Fract V), sodium pyruvate, and gentamicin to make SP-TALP (Tyrode's Albumin Lactate Pyruvate). |
Cyclic citrullinated peptide-BSA(CCP-BSA) |
E64I00802 |
EnoGene |
100ug |
EUR 411.6 |
Gentamicin Sulfate Solution (50 mg/mL in Water) |
G046-20ML |
TOKU-E |
20 mL |
EUR 132 |
Anti-Gentamicin antibody *Mouse anti-human, monoclonal IgG1* |
V100270 |
AAT Bioquest |
50 ug |
EUR 367.2 |
|
Anti-Gentamicin antibody *Mouse anti-human, monoclonal IgG1* |
V100271 |
AAT Bioquest |
1 mg |
EUR 1306.8 |
|
BSA antibody |
70C-CR1016GAP |
Fitzgerald |
1 mg |
EUR 516 |
Description: Affinity purified Goat polyclonal BSA antibody |
BSA antibody |
70R-12462 |
Fitzgerald |
100 ug |
EUR 552 |
Description: Rabbit polyclonal BSA antibody |
LSD-BSA |
65R-1007 |
Fitzgerald |
1 mg |
EUR 891.6 |
Description: LSD-BSA Conjugated Hapten |
BSA antibody |
70-BC67 |
Fitzgerald |
1 mg |
EUR 229.2 |
Description: Affinity purified Chicken polyclonal BSA antibody |
BSA antibody |
10-1911 |
Fitzgerald |
200 ul |
EUR 651.6 |
Description: Mouse monoclonal BSA antibody |
BSA Antibody |
48061-100ul |
SAB |
100ul |
EUR 399.6 |
BSA Antibody |
48061-50ul |
SAB |
50ul |
EUR 286.8 |
BSA Antibody |
35643-100ul |
SAB |
100ul |
EUR 302.4 |
BSA antibody |
20R-AR042 |
Fitzgerald |
20 mg |
EUR 392.4 |
Description: Rabbit polyclonal BSA antibody |
BSA antibody |
10R-10573 |
Fitzgerald |
100 ul |
EUR 418.8 |
Description: Mouse monoclonal BSA antibody |
BSA antibody |
10R-A139B |
Fitzgerald |
500 µg |
EUR 925.2 |
Description: Mouse monoclonal BSA antibody |
BSA antibody |
20R-1871 |
Fitzgerald |
100 ug |
EUR 807.6 |
Description: Rabbit polyclonal BSA antibody |
BSA antibody |
10R-1795 |
Fitzgerald |
100 ul |
EUR 522 |
Description: Mouse monoclonal BSA antibody |
Acetylcholine (BSA) |
20-abx165621 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Allopregnanolone (BSA) |
20-abx165627 |
Abbexa |
-
EUR 678.00
-
EUR 309.60
-
EUR 1963.20
-
EUR 794.40
-
EUR 493.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Androstenediol (BSA) |
20-abx165635 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Androstenedione (BSA) |
20-abx165637 |
Abbexa |
-
EUR 710.40
-
EUR 309.60
-
EUR 2131.20
-
EUR 844.80
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Bilirubin (BSA) |
20-abx165653 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carmine (BSA) |
20-abx165660 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carnitine (BSA) |
20-abx165662 |
Abbexa |
-
EUR 627.60
-
EUR 292.80
-
EUR 1796.40
-
EUR 727.20
-
EUR 460.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cholesterol (BSA) |
20-abx165666 |
Abbexa |
-
EUR 727.20
-
EUR 309.60
-
EUR 2180.40
-
EUR 861.60
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cortisol (BSA) |
20-abx165679 |
Abbexa |
-
EUR 678.00
-
EUR 309.60
-
EUR 1996.80
-
EUR 794.40
-
EUR 493.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cyanocobalamin (BSA) |
20-abx165692 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dehydroepiandrosterone (BSA) |
20-abx165700 |
Abbexa |
-
EUR 627.60
-
EUR 292.80
-
EUR 1796.40
-
EUR 727.20
-
EUR 460.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Deoxycholate (BSA) |
20-abx165702 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dihydrotestosterone (BSA) |
20-abx165704 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dipalmitin (BSA) |
20-abx165706 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dopamine (BSA) |
20-abx165709 |
Abbexa |
-
EUR 844.80
-
EUR 343.20
-
EUR 2598.00
-
EUR 994.80
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Epinephrine (BSA) |
20-abx165713 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Estradiol (BSA) |
20-abx165715 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Estriol (BSA) |
20-abx165717 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Ethinylestradiol (BSA) |
20-abx165719 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
gABA (BSA) |
20-abx165727 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Glutathione (BSA) |
20-abx165738 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Glycine (BSA) |
20-abx165740 |
Abbexa |
-
EUR 727.20
-
EUR 309.60
-
EUR 2180.40
-
EUR 861.60
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Guanosine (BSA) |
20-abx165742 |
Abbexa |
-
EUR 627.60
-
EUR 292.80
-
EUR 1796.40
-
EUR 727.20
-
EUR 460.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Heparin (BSA) |
20-abx165746 |
Abbexa |
-
EUR 661.20
-
EUR 292.80
-
EUR 1914.00
-
EUR 777.60
-
EUR 493.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Histamine (BSA) |
20-abx165751 |
Abbexa |
-
EUR 661.20
-
EUR 292.80
-
EUR 1914.00
-
EUR 777.60
-
EUR 493.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Homocysteine (BSA) |
20-abx165753 |
Abbexa |
-
EUR 744.00
-
EUR 326.40
-
EUR 2230.80
-
EUR 878.40
-
EUR 543.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Hydroxyproline (BSA) |
20-abx165759 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Lysophosphatidylcholine (BSA) |
20-abx165773 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Malondialdehyde (BSA) |
20-abx165775 |
Abbexa |
-
EUR 744.00
-
EUR 326.40
-
EUR 2230.80
-
EUR 878.40
-
EUR 543.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Melatonin (BSA) |
20-abx165777 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Nitrotyrosine (BSA) |
20-abx165786 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Noradrenaline (BSA) |
20-abx165787 |
Abbexa |
-
EUR 710.40
-
EUR 309.60
-
EUR 2131.20
-
EUR 844.80
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Phosphatidylinositol (BSA) |
20-abx165798 |
Abbexa |
-
EUR 627.60
-
EUR 292.80
-
EUR 1796.40
-
EUR 727.20
-
EUR 460.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Phosphatidylserine (BSA) |
20-abx165800 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Progesterone (BSA) |
20-abx165806 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Tartrazine (BSA) |
20-abx165824 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Testosterone (BSA) |
20-abx165826 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Thyroxine (BSA) |
20-abx165834 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Triiodothyronine (BSA) |
20-abx165836 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Oxycodone (BSA) |
abx080015-1mg |
Abbexa |
1 mg |
EUR 1429.2 |
|
Phenobarbital (BSA) |
abx080016-1mg |
Abbexa |
1 mg |
EUR 994.8 |
|
THC (BSA) |
abx080017-1mg |
Abbexa |
1 mg |
EUR 510 |
|
Barbiturate (BSA) |
abx080026-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Benzodiazepine (BSA) |
abx080027-1mg |
Abbexa |
1 mg |
EUR 460.8 |
|
Buprenorphine (BSA) |
abx080028-1mg |
Abbexa |
1 mg |
EUR 543.6 |
|
Benzolecgonine (BSA) |
abx080029-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Benzolecgonine (BSA) |
abx080030-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Methamphetamine (BSA) |
abx080031-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Morphine (BSA) |
abx080032-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Morphine (BSA) |
abx080033-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Morphine (BSA) |
abx080034-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Methadone (BSA) |
abx080035-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Oxycodone (BSA) |
abx080036-1mg |
Abbexa |
1 mg |
EUR 444 |
|
Amphetamine (BSA) |
abx080037-1mg |
Abbexa |
1 mg |
EUR 444 |
|
EDDP (BSA) |
abx080038-1mg |
Abbexa |
1 mg |
EUR 844.8 |
|
Ketamine (BSA) |
abx080046-1mg |
Abbexa |
1 mg |
EUR 543.6 |
|
Analytical Efficiency of thrombospondin-1 and Cathepsin D Immunoassays A part of a Novel CE-IVD Marked Take a look at as an Support within the Prognosis of Prostate Most cancers
The Prostate Particular Antigen (PSA) take a look at suffers from low specificity for the prognosis of Prostate Most cancers (PCa). We initially found two cancer-related proteins thrombospondin-1 (THBS1) and cathepsin D (CTSD) utilizing a mass-spectrometry-based proteomics method. The 2 serum proteins have been proven to enhance the prognosis of high-grade PCa. Thus, we developed quantitative ELISAs for the dedication of their focus in human serum. Right here we report their analytical efficiency by way of restrict of detection, specificity, precision, linearity and interferences, which have been decided based mostly on CLSI pointers. Additional, we investigated the affect of pre-analytical elements on focus measurements.
For this, blood from 4-6 donors was collected in several tubes and saved at room temperature for various occasions previous to centrifugation at completely different centrifugal forces and temperatures. Stability of THBS1 and CTSD underneath completely different storage temperatures was additionally evaluated. Our outcomes present that the assays are particular, linear and delicate sufficient to permit measurement of scientific samples. Precision by way of repeatability and complete within-laboratory coefficient of variation (CV) are 5.5% and eight.1% for THBS1 and 4.3% and seven.2% for CTSD, respectively.
Relative laboratory-to-laboratory variations have been -6.3% for THBS1 and -3% for CTSD. Each THBS1 and CTSD have been secure in serum samples, with 80-120% recoveries of concentrations throughout donors, pattern preparation and storage. In conclusion, the ELISAs as a part of the novel business in vitro diagnostic take a look at Proclarix are appropriate for the use in scientific follow. THBS1 and CTSD will be precisely measured for his or her meant use impartial of the lot and laboratory when situations in step with routine follow for PSA sampling and storage are used.
Degenerative IVD Conditioned Media and Acidic pH Sensitize Sensory Neurons to Cyclic Tensile Pressure.
Low again ache is amongst the main causes of incapacity worldwide. The degenerative intervertebral disc (IVD) setting accommodates pathologically excessive ranges of inflammatory cytokines and acidic pH hypothesized to contribute to again ache by sensitizing nociceptive neurons to stimuli that will not be painful in wholesome sufferers. We hypothesized that the degenerative IVD setting drives discogenic ache by sensitizing nociceptive neurons to mechanical loading. To check this speculation, we developed an in vitro mannequin that facilitated the investigation of interactions between the degenerative IVD setting, nociceptive neurons innervating the IVD and mechanical loading of the disc; and, the identification of the underlying mechanism of degenerative IVD induced nociceptive neuron sensitization.
In our mannequin, rat DRG neurons have been seeding onto bovine AF tissue, uncovered to degenerative IVD conditioned media and/or acidic pH, and subjected to cyclic tensile pressure (1 Hz; 1-6 % pressure) throughout measurement of DRG sensory neuron exercise through calcium imaging. Utilizing this mannequin, we demonstrated that each degenerative IVD conditioned media and degenerative IVD acidic pH ranges induced elevated nociceptive neuron activation in response to physiologic ranges of mechanical pressure. As well as, IL-6 was demonstrated to mediate degenerative IVD conditioned media induced elevated nociceptive neuron activation.
These outcomes show IL-6 mediates degenerative IVD induced neuron sensitization to mechanical loading and additional establishes IL-6 as a possible therapeutic goal for the therapy of discogenic ache. Information additional suggests the degenerative IVD setting accommodates a number of neuron sensitization pathways (IL-6, pH) which will contribute to discogenic ache. This text is protected by copyright. All rights reserved
Fast Detection of KPC-Producing Enterobacterales Prone to Imipenem/Relebactam by Utilizing the MALDI-TOF MS MBT STAR-Carba IVD Assay.
KPC-producing Enterobacterales signify a severe public well being concern. Restricted therapeutic choices can be found for therapy, nonetheless, the novel mixture of imipenem/relebactam represents a promising different. To protect the exercise of this new antibiotic mixture, solely focused therapies will likely be really helpful, and speedy checks to detect prone micro organism are subsequently urgently wanted. Right here, we suggest a MALDI-TOF-based methodology utilizing the MBT STAR-Carba IVD assay, Bruker Daltonik, to detect KPC-producing Enterobacterales prone to imipenem/relebactam in a random collection of 143 scientific isolates earlier molecular characterised, carrying 97 blaKPC, 1 blaGES, 12blaVIM, 4blaIMP, 3blaNDM, and 26blaOXA-48-like. Species identification was confirmed by MALDI-TOF MS.
The molecular characterization of the isolates was carried out by the Xpert Carba-R Assay and the outcomes have been used as gold normal. In addition to, all isolates have been submitted to imipenem and imipenem/relebactam microdilution susceptibility testing. The assay confirmed an general sensitivity and specificity to detect class A-producing Enterobacterales prone to imipenem/relebactam of 98% (96/98) and 93% (42/45), respectively. This MALDI-TOF-based methodology, with a turnaround time of lower than 1 h, is a dependable take a look at for detecting imipenem/relebactam exercise and its inclusion in routine laboratory screening would facilitate the proper use of this new mixture of antimicrobials as a focused therapy.
Rising a spine – purposeful biomaterials and buildings for intervertebral disc (IVD) restore and regeneration: challenges, improvements, and future instructions.
Again ache and related maladies can account for an immense quantity of healthcare value and lack of productiveness within the office. Particularly, backbone associated accidents within the US have an effect on upwards of 5.7 million folks annually. The degenerative disc illness therapy virtually all the time arises attributable to a scientific presentation of ache and/or discomfort. Most popular conservative therapy modalities embrace the usage of non-steroidal anti-inflammatory drugs, bodily remedy, therapeutic massage, acupuncture, chiropractic work, and dietary dietary supplements like glucosamine and chondroitin. Synthetic disc substitute, also referred to as complete disc substitute, is a therapy different to spinal fusion. The purpose of synthetic disc prostheses is to copy the conventional biomechanics of the backbone section, thereby stopping additional injury to neighboring sections.
Synthetic purposeful disc substitute via everlasting steel and polymer-based parts continues to evolve, however is way from recapitulating native disc construction and performance, and suffers from the danger of unsuccessful tissue integration and machine failure. Tissue engineering and regenerative medication methods mix novel materials buildings, bioactive elements and stem cells alone or together to restore and regenerate the IVD.
These efforts are at very early phases and a extra in-depth understanding of IVD metabolism and mobile setting may even result in a clearer understanding of the native setting which the tissue engineering scaffold ought to mimic. The present overview focusses on the methods for a profitable regenerative scaffold for IVD regeneration and the necessity for outlining new supplies, environments, and elements which might be so finely tuned within the wholesome human intervertebral disc in hopes of treating such a prevalent degenerative course of.